13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • AGENUS

    Acronym: 

    AGENUS

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase I, Phase II Tumour Stream Cervical
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Sex Female Anticipated Start Date 2019-09-01
    Molecular Target Anticipated End Date
    Cancer Type Gynaecological
    Trial Type Treatment
    Phase Phase I, Phase II
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Cervical
    Cancer Stage Locally Recurrent or Locally Advanced, Metastatic or Widespread
    Anticipated Start Date 2019-09-01
    Anticipated End Date

    Trial Summary

    A phase I/ II, open-label, multiple ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of AGEN2034 in subjects with metastatic or locally advanced solid tumours, with expansion to second line cervical cancer

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Recruiting